Phase II evaluation of maytansine in patients with metastatic lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008453:Maytansine / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010078:Oxazines / Q000627:therapeutic use*
D010078:Oxazines; D008453:Maytansine